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AbstrAct
Objective to describe the methodology used to develop 
new classification criteria for adult and juvenile idiopathic 
inflammatory myopathies (iiMs) and their major subgroups.
Methods an international, multidisciplinary group 
of myositis experts produced a set of 93 potentially 
relevant variables to be tested for inclusion in the criteria. 
rheumatology, dermatology, neurology and paediatric 
clinics worldwide collected data on 976 iiM cases (74% 
adults, 26% children) and 624 non-iiM comparator cases 
with mimicking conditions (82% adults, 18% children). 
the participating clinicians classified each case as iiM or 
non-iiM. generally, the classification of any given patient 
was based on few variables, leaving remaining variables 
unmeasured. We investigated the strength of the association 
between all variables and between these and the disease 
status as determined by the physician. We considered three 
approaches: (1) a probability-score approach, (2) a sum-of-
items approach criteria and (3) a classification-tree approach.
Results the approaches yielded several candidate 
models that were scrutinised with respect to statistical 
performance and clinical relevance. the probability-
score approach showed superior statistical performance 
and clinical practicability and was therefore preferred 
over the others. We developed a classification tree for 
subclassification of patients with iiM. a calculator for 
electronic devices, such as computers and smartphones, 
facilitates the use of the european league against 
rheumatism/american college of rheumatology (eUlar/
acr) classification criteria.
Conclusions the new eUlar/acr classification criteria 
provide a patient’s probability of having iiM for use in 
clinical and research settings. the probability is based 
on a score obtained by summing the weights associated 
with a set of criteria items.
Key messages
What is already known about this subject?
 ► currently, the most often used criteria for idiopathic 
inflammatory myopathies stem from 1975, are 
based on expert opinion, hence not data driven, and 
are used interchangeably as both diagnostic and 
classification criteria.
What does this study add?
 ► this report describes a new methodology to 
develop classification criteria based on patient data. 
the individual variables have been given different 
weights and different scores. the method is based 
on calculations of probability to define a case as 
having myositis or non-myositis, which gives a 
flexibility of the number of variables needed to be 
tested.
 ► a web-based calculator has been developed that 
facilitates defining a case as myositis and also 
defining myositis subgroup.
How might this impact on clinical practice?
 ► this study provides information on a new 
methodology to develop classification criteria 
combined for adult and children with myositis and 
to be used for clinical studies, research and trials.
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InTROduCTIOn
The first European League Against Rheumatism/Amer-
ican College of Rheumatology (EULAR/ACR) classifi-
cation criteria for idiopathic inflammatory myopathies 
(IIMs), collectively known as myositis, and the major 
subgroups of IIM have been developed.1 This report 
describes the methodological approach used for the 
development of the criteria. Detailed information about 
the classification criteria is given in the companion 
article.1 
IIMs are a group of rare and heterogeneous diseases, 
involving different medical specialties in patient treat-
ment and care, as well as research. Currently, the most 
often used criteria for IIM were defined based on 
expert opinion more than 40 years ago. An interna-
tional and multidisciplinary collaboration, the Interna-
tional Myositis Classification Criteria Project (IMCCP), 
was established comprising rheumatologists, paediatric 
rheumatologists, neurologists, dermatologists, epidemi-
ologists and biostatisticians. The group addressed both 
childhood-onset and adult-onset IIMs, following the ACR 
and EULAR recommendations for development of classi-
fication criteria.2 3 A large group of experts accepted the 
task, and a steering committee was appointed. A wider 
group of investigators formed a working committee that 
contributed clinical data and clinical expertise to the 
study. Major professional societies and interest groups 
(listed in the Methods section) in the field of myositis 
research and clinical care provided endorsement and 
support, and participated in the project. This led to the 
development of the EULAR/ACR classification criteria 
for IIM and their major subgroups.
MeTHOds
The ACR, EULAR, American Academy of Neurology, the 
Childhood Arthritis and Rheumatology Research Alli-
ance, the European Neuromuscular Centre (ENMC), the 
International Myositis Assessment and Clinical Studies 
Group (IMACS), the Muscle Study Group, the Rheuma-
tologic Dermatology Society, the Pediatric Rheumatology 
European Society network for JDM and the Pediatric 
Rheumatology International Trials Organization contrib-
uted to this project.
selection of criteria items
The steering committee had a face-to-face meeting to 
detail the study design. It was decided what IIM diagnoses 
would be included in the study along with comparator 
cases having conditions that were commonly confused 
with IIM.1 The committee generated candidate criteria 
based on previously published myositis criteria,4–16 and 
new items that had been described since the previous 
criteria were developed and considered relevant charac-
teristics of IIM. A pilot feasibility study was conducted to 
assess the practicality and the likelihood that these vari-
ables could be collected from existing medical records. 
The list of items was modified and presented again for 
discussion in a face-to-face meeting, with experts of the 
working committee achieving consensus on items for 
inclusion in the study, through a nominal group tech-
nique17–20 to ensure face and content validity of the 
items.2 3 Members of the working committee were asked 
to choose the 10 items on the list they considered most 
important. Consensus items were defined and distrib-
uted to a large network of experts through the IMACS 
membership list for further comments and input via 
a Delphi email method. These were discussed by the 
steering committee, and a final list was agreed on. Each 
variable was defined using the ACR nomenclature list.21 22
data collection
A web-based questionnaire was created on SurveyMonkey 
(www. surveymonkey. com) (online supplementary table 
S1). Members of the IMCCP working committee and the 
IMACS network were asked to contribute IIM cases and 
comparators. An initial power calculation was based on 
an expected enrolment of 150 patients in each of the 
following subgroups: polymyositis (PM), dermatomy-
ositis (DM), juvenile dermatomyositis (JDM), inclusion 
body myositis (IBM), other IIM cases and 500 compara-
tors. Clinical data were abstracted from patients’ records.
Inclusion criteria for cases and comparators were (1) 
diagnosis for at least 6 months prior to study inclusion; 
(2) physician certainty of diagnosis, either known IIM or, 
as comparators, known non-IIM cases where myositis was 
considered in the initial differential diagnosis; and (3) 
patients with the most recent and complete data were 
prioritised to acquire the most complete data in a consis-
tent manner.
To ensure a balanced number of cases across sites, a 
maximum of 40 cases and an equal number of compara-
tors were collected from each centre. Cases were chosen 
based on the certainty of diagnosis and completeness 
of the variables being collected. In paediatric centres, a 
minimum of five cases and five comparators was required. 
The study was approved or exempted from approval by 
ethics committees at each participating clinic.
data processing
Before proceeding with the analyses, the available data 
were checked for accuracy and quality. In addition, 
univariate and bivariate frequency distributions were 
compared with those produced directly by the Survey-
Monkey server. All variables were grouped into catego-
ries: muscle, skin, laboratory, biopsies, MRI, electromyo-
gram (EMG) and others. Non-informative responses and 
data errors were coded as missing (online supplementary 
table S2).
Most variables were dichotomous. Age was grouped 
into three categories (0–17, 18–39, 40+ years) in the anal-
yses. The cut-off values were selected because they corre-
sponded to clinically accepted age categories. In addition, 
they maximised the goodness of fit of the probabili-
ty-score model described in the section titled 'Methods 
to develop new classification criteria.' The association 
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of each variable with the diagnosis (IIM, non-IIM) was 
assessed by ORs and tested with the Fisher’s exact test. 
The associations among all predictors were also evalu-
ated. Strong associations indicated that different predic-
tors provided near equivalent information.
The participating clinicians specialising in myositis 
often diagnosed patients based on only a few variables 
in the data entry form, leaving the other variables blank. 
Blanks were considered missing observations in the data 
analyses. Because it was the doctor’s decision what vari-
ables to measure and what to leave blank, the missing 
observations were assumed to be generated by a miss-
ing-at-random mechanism.23 We carefully inspected all 
the patterns of missing values across all the patients in 
the dataset. As sensitivity analysis, we explored the possi-
bility of coding all missing values as a separate category. 
This, however, did not improve the performance of the 
resulting classification criteria.
Stata statistical software (StatCorp, College Station, 
Texas, USA) was used for data management and statis-
tical analyses. R statistical software was used for part of 
the analyses of classification trees and random forests.
Methods to develop new classification criteria
We used three methods to develop the criteria: (1) a 
probability score, (2) a sum of items and (3) a classifica-
tion tree. Each approach was developed independently 
of the others. The variables identified by one approach 
as potentially relevant predictors were compared with 
those selected from the other approaches in an iter-
ative process. The items that finally emerged as poten-
tially relevant for the prospective criteria were closely 
examined for statistical performance, clinical relevance 
and practicability by the steering committee. Statistical 
performance was measured by classification accuracy and 
area under the receiver operating characteristic curve. 
Internationally, there is wide variation in whether muscle 
biopsy is felt mandatory, possible or routinely done or 
available in suspected myositis. Recognising the realities 
of practice, the committee felt that standardisation and 
transparency would be best served by having one set of 
criteria when biopsies are available and another when 
they are not.
Probability-score approach
A probability-score model consists of items (eg, signs, 
symptoms, laboratory measures) that can be observed 
in a patient. A score value is assigned to each item. The 
total score for a patient is obtained by summing the score 
values associated with the items observed. The total score 
is converted to a probability by a formula or by inspection 
from a graph. A small subset of items generally permits 
classifying a patient as an IIM case or a non-case. The set 
of relevant items, however, differs between subgroups of 
the IIM disease.
The score values of the candidate items were estimated 
by multivariable logistic regression. Initially, all variables 
were included one at a time and those having the largest 
numbers of observations and strongest associations with 
the diagnosis were identified. In addition to each indi-
vidual item, new variables from each category (muscle, 
skin, other signs and symptoms, biopsy, laboratory data 
and EMG) were assigned a 1 if present and a value of 
zero if absent. These indicator variables and individual 
items were entered into a multivariable model one at a 
time. The statistical significance of the resulting increase 
in the goodness of fit of the model was assessed by Wald 
tests. The predictive ability was measured by their clas-
sification accuracy, specificity and sensitivity, and area 
under the receiver operating characteristic curve. When 
the estimated regression coefficients associated with 
predictors from the same group were similar, but the 
predictors were not measured jointly, we defined a new 
item as present if any of these predictors were present. 
An example of this type of items is represented by second 
item in the laboratory section of the EULAR/ACR clas-
sification criteria reported in table 1 (CK, LDH, ASAT/
AST/SGOT or ALAT/ALT/SGPT). Only models with 
valid observations on at least 800 subjects, half of the 
sample, were considered (online supplementary table 
S2). When the analyses were done in children (<18 years) 
and adults (18+ years) separately, the score points did 
not change much, with correlation coefficients ranging 
between 0.98 and 1.00.
The overall aim was to derive an accurate, parsi-
monious and easy-to-use model based on variables 
commonly observed. Hence, the content validity and 
clinical feasibility of each variable was considered before 
entering it into the model. Some aspects of the statistical 
performance of the classification criteria were validated 
internally and externally on independent datasets, as 
described below.
Sum-of-item approach
This approach has been used by most of the previously 
published criteria.7–11 14 15 A patient is classified as case if 
the patient has a certain number of items out of a prespec-
ified set of items. The sum-of-item approach is a special 
case of the more general probability-score approach 
described above in which all the constituent items are 
assigned a score value of 1. When the score values are all 
equal to 1, summing the score values associated with the 
items that are present is equivalent to simply counting 
them. Counting the items that are present may be slightly 
simpler than summing their score values. However, the 
resulting classification criteria become substantially 
less flexible. While the clinical feasibility of the sum-of-
item approach was comparable with that of the proba-
bility-score approach, the statistical performance of the 
former was considerably poorer than that of the latter. 
The sum-of-score approach was therefore abandoned.
classification-tree approach
A classification tree starts with a specific item and branches 
into two possible paths depending on whether or not the 
item is observed in the patient. A binary split is applied 
4 Bottai M, et al. RMD Open 2017;3:e000507. doi:10.1136/rmdopen-2017-000507
RMD Open
to multicategory variables. This is repeated until the tree 
ends in a leaf that is labelled either IIM or non-IIM.
Classification trees and random forests were estimated 
by using standard machine-learning algorithms.24 The 
first tree was obtained by selecting variables from the pool 
of all the variables available. Missing data were imputed 
with random forest algorithms beforehand. The random 
forests provided information on what variables could 
represent important predictors. Subsequently, trees were 
obtained from subsets of all the available variables. Only 
those that showed strong univariate associations, or used 
in published criteria,7–11 14 15 or appeared most informa-
tive in the random forest analysis, and had the largest 
number of valid observations were used.
The classification-tree approach was clinically feasible, 
and a number of different trees had similar statistical 
performance.
Validation
The probability score was validated internally and exter-
nally on independent datasets. For the internal validation, 
bootstrap resampling techniques were used to estimate 
prediction error and discrimination ability of the candi-
date classification criteria.25 The external validation of 
the classification criteria was based on two large external 
datasets. These datasets contained IIM cases only, and 
only the sensitivity of the criteria could be assessed. 
Details about the external datasets and the results of the 
validation process are given in the companion article.1
subgroups of IIM defined by classification tree
A classification tree was developed to distinguish 
subgroups of patients classified with IIM according to the 
new criteria. The tree was based on the variables in the 
new classification criteria and on expert opinion. More 
details on this are provided in the companion article.1
Online calculator
To facilitate the use of the EULAR/ACR classification 
criteria, an informational and instructional webpage and 
online calculator was developed (http://www. imm. ki. se/ 
biostatistics/ calculators/ iim). The calculator computes a 
range for the probability of IIM. It is free to download and 
requires no internet connection to use. When sufficient 
Table 1 Score points for the European League Against Rheumatism/American College of Rheumatology classification criteria 
for adult and juvenile idiopathic inflammatory myopathies to be used when no better explanation for the symptoms or signs 
exists1
Variable
Score points
No biopsy Biopsy
Age of onset of first related symptoms
  18–40 1.3 1.5
  ≥40 2.1 2.2
Muscle weakness
  Objective symmetric weakness, usually progressive, of proximal upper extremities 0.7 0.7
  Objective symmetric weakness, usually progressive, of proximal lower extremities 0.8 0.5
  Neck flexors are relatively weaker than neck extensors 1.9 1.6
  In the legs, proximal muscles are relatively weaker than distal muscles 0.9 1.2
Skin manifestations
  Heliotrope rash 3.1 3.2
  Gottron’s papules 2.1 2.7
  Gottron’s sign 3.3 3.7
Other clinical manifestations
  Dysphagia or esophageal dysmotility 0.7 0.6
Laboratory measurements
  Anti-Jo-1 (anti-histidyl-tRNA synthetase) autoantibody positivity 3.9 3.8
  Elevated serum levels of creatine kinase (CK)* or lactate dehydrogenase (LDH)* or aspartate 
aminotransferase (ASAT/AST/SGOT)* or alanine aminotransferase (ALAT/ALT/SGPT)*
1.3 1.4
Muscle biopsy features
  Endomysial infiltration of mononuclear cells surrounding, but not invading, myofibres 1.7
  Perimysial and/or perivascular infiltration of mononuclear cells 1.2
  Perifascicular atrophy 1.9
  Rimmed vacuoles 3.1
*Serum levels above upper limit of normal.
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information is entered, the subclassification is displayed. 
It can be used on any device that supports Java scripts, 
including most web browsers. A Microsoft Excel spread-
sheet can also be downloaded. The website is maintained 
by the Unit of Biostatistics, Karolinska Institutet, Stock-
holm, Sweden.
Face and construct validation
All project participants were invited to a face-to-face 
meeting to provide input on the different approaches, 
classification criteria and results. In addition, three 
web-based meetings for all project participants were held 
as part of the face and construct validation.
ResulTs
Assembly of subjects with IIM and comparators
Data from 976 IIM (74% adults; 26% children) and 624 
comparators (82% adults; 18% children) were collected 
from 17 North American, 1 South American, 23 Euro-
pean and 6 Asian clinics, between 2008 and 2011. The IIM 
cases comprised all the included subgroups. The non-IIM 
cases represented a broad spectrum of mimicking condi-
tions (defined in Lundberg et al1).
data analysis and development of classification criteria
A final list of 93 candidate classification criteria items to 
be collected in the questionnaire was defined. The list 
included demographic data, clinical muscle variables, 
skin variables, other clinical variables of importance, 
laboratory variables comprising muscle enzyme measure-
ments, inflammation marker measurements and autoan-
tibody tests, EMG and MRI characteristics of muscle 
and muscle biopsy features determined by conventional 
histopathological examination, immunohistochemical 
staining and electron microscopy (EM) (online supple-
mentary table S1).
The variables corresponding to muscle weakness 
patterns and skin manifestations had the highest numbers 
of valid observations (online supplementary table S2). 
The mean numbers of observations across all variables in 
the muscle category and in the skin category were 1394 
and 1506, respectively. The variables relating to EMG and 
MRI measurements, immunohistochemical staining of 
muscle and EM examination of muscle biopsy had the 
fewest observations (mean number of observations equal 
to 602, 465, 277 and 121, respectively). The variables with 
highest ORs associated with IIM were skin manifestations, 
and in particular heliotrope rash (OR 32.4), Gottron’s 
papules (OR 26.8) and Gottron’s sign (OR 30.5). The 
associations of predictors showed strong and significant 
associations between variables within the same catego-
ries, such as muscle weakness pattern and skin manifes-
tations as two clinical variables, but not across different 
categories.
The probability-score approach was used to derive two 
sets of criteria: one when muscle biopsies are available 
and the other when they are not. Table 1 shows the score 
points for the calculation of the probability associated 
with each of the items contained in the two sets. Both 
sets include age, patterns of muscle weakness, skin mani-
festations, dysphagia, elevated muscle enzyme levels in 
sera and anti-Jo-1 autoantibodies in sera. One of the two 
sets also includes muscle biopsy features. The total score 
is obtained by adding the score points corresponding to 
all items present in the patient, as shown in table 1. The 
score can be converted to a probability of IIM visually on 
figure 1A and B or by using the following formulas:
 
Probability of IIM = 1/(1 + exponential function(5.33− score)) 
 
Probability of IIM = 1/(1 + exponential function(6.49− score)) 
 
The first formula is to be used when muscle biopsies are 
available; the second when they are not.
The score points shown in table 1 are calculated as 
the estimated logistic regression coefficients rounded 
to the first decimal digit. A constant term was included 
in the model, but it is not shown in table 1. Its value is 
subtracted from the score instead, as indicated in the 
formulas displayed above. The web calculator does not 
round the value of the logistic regression coefficients. 
This may result in small differences in the probability as 
calculated by the web calculator or by hand from table 1.
The score points reported in table 1 can be used to 
obtain a range for the probability of IIM as follows: when 
no items are observed, the probability of IIM ranges 
from zero to one. When some, but not all, items are 
observed, the probability ranges from smallest to largest 
possible value. The smallest possible value is calculated 
by replacing all the unobserved items with ‘absent’. The 
largest possible value is obtained by replacing all the 
unobserved values with ‘present’. This is conveniently 
implemented in the web calculator. When all items are 
observed, the smallest and the largest possible probability 
values coincide. However, the probability range quickly 
narrows as soon as a few items are observed and quickly 
moves away from the 50% probability towards either 0% 
or 100%.
A patient is classified as an IIM case if the patient’s prob-
ability is above a specified cut-off value. The best balance 
between sensitivity and specificity (figure 1) is obtained 
for a cut-off of 55%–60% for the criteria not including 
muscle biopsy data (panel C) and 55%–75% for when 
muscle biopsy data are included (panel D). Based on 
these results, a cut-off of 55% (a total aggregate score of 
5.5 without biopsies; 6.7 with biopsies) was decided by 
the steering committee as the minimal level to classify 
a case as IIM. The IMCCP steering committee recom-
mends that ‘high probability’ of IIM should be defined 
as 90% or greater. Patients with a probability of ≥55% to 
<90% are designated ‘probable IIM’. A probability 
of ≥90%, or a total aggregate score of ≥7.5 without muscle 
biopsy and ≥8.7 with muscle biopsy, corresponds to ‘defi-
nite IIM’, and a probability ≥50% to <55% is termed 
‘possible IIM’.
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subgroup classification tree
This section also appears in the companion paper.1 A 
patient classified with IIM by the EULAR/ACR classifi-
cation criteria probability score can be further subclassi-
fied applying a classification tree (figure 2). Age at onset 
of first symptom distinguishes adult from juvenile IIM. 
Thereafter, clinical findings and muscle biopsy features 
subclassify adult patients with IIM into PM, IBM, ADM or 
DM. Based on our dataset, juvenile patients with skin rash 
can be classified into JDM. Three subgroups cannot be 
further separated because of small sample sizes: juvenile 
PM, immune-mediated necrotising myopathy (IMNM) 
and hypomyopathic DM.
Among patients with IIM by the EULAR/ACR classifi-
cation criteria, and with sufficient data to allow subclassi-
fication (n=703), the number of cases in the subgroups as 
defined according to the classification tree was enumer-
ated (online supplementary table S3). The agreement 
between the classification tree subgroups and the physi-
cian-diagnosed subgroups in the dataset was high (92.6% 
agreement, kappa=0.90, P<0.00001). The agreement 
proportions, with a probability of 55%, were 1.00 for 
JDM, 0.89 for DM, 0.94 for ADM, 0.92 for IBM and 0.93 
for PM. Raising the probability cut-off of IIM to 90% 
yielded 94.9% agreement, kappa=0.93, P>0.00001. With 
a probability cut-off of 90%, the agreement proportions 
were 1.00 for JDM, 0.96 for DM, 0.95 for ADM, 0.93 for 
IBM and 0.88 for PM.
Face and construct validation
Twenty-three project participants attended a face-to-
face meeting and provided input on project process and 
results. They also gave suggestions towards facilitating 
the face and construct validity process among myositis 
experts. In total, 26 project participants took part in 
web-based seminars arranged where data collection, data 
analysis, the classification criteria, their performance 
and real case demonstrations were vetted. The myositis 
experts expressed ‘satisfaction’ with respect to both 
credibility and comprehensiveness of the classification 
criteria.
dIsCussIOn
The EULAR/ACR classification criteria for IIM were 
developed by a large international and multidisciplinary 
group of 100 myositis experts.1 These criteria provide 
a probability of IIM and can be used with adults and 
children. A patient is classified as an IIM case when 
this probability is above 55%. The development of the 
criteria was based on empirical data, guided by clinical 
and statistical expertise. The EULAR/ACR IIM classifi-
cation criteria showed greater sensitivity and specificity 
Figure 1 European League Against Rheumatism/American College of Rheumatology classification criteria probability of 
having idiopathic inflammatory myopathies (IIMs) over total score values. The total score is obtained from adding up the score 
values in table 1. Panel A corresponds to total score without muscle biopsy data and panel B with muscle biopsy data. Each 
score and probability of disease display a unique set of sensitivity (blue line) and specificity (red line) measurement for the 
classification criteria not including muscle biopsy data (C) or including muscle biopsy data (D). The optimal point of accuracy 
should be stated in publications and appropriate to the intended purpose, with the recommendation of using a minimum of 
55% probability (score of 5.5 without biopsies; 6.7 with biopsies) for classifying a case as IIM (‘probable IIM’) (dotted line). 
‘Definite IIM’ corresponds to a probability of at least 90% (score of 7.5 without biopsies; 8.7 with biopsies).
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than the often-used Bohan and Peter’s criteria,7 8 and 
at least as high as other published myositis classification 
criteria and a higher sensitivity than the newer ENMC 
criteria.9–11 14 15 The sensitivity of the EULAR/ACR IIM 
classification criteria was externally validated in inde-
pendent cohorts of patients with IIM and effectively 
captures all myositis subgroups included in the IMCCP 
study.
Myositis is a rare disease with multiple heterogeneous 
subgroups. Patients may be examined by physicians from 
various medical disciplines. Developing new classifica-
tion criteria therefore called for adequately sized multi-
centre studies and involvement of representatives from 
all relevant medical disciplines. The IMCCP is the largest 
clinical myositis study to date. Experts from five different 
medical and methodological disciplines from all over the 
world collaborated to ensure its successful completion.
Unlike most previously published myositis diagnostic 
and classification criteria, the EULAR/ACR IIM classifi-
cation criteria are based on clinical information collected 
from adult and juvenile patients with myositis and 
comparators from Europe, North and South America, 
and Asia. While previous criteria assign equal weight to 
their criteria items, the EULAR/ACR IIM classification 
criteria assign different weights, each reflecting the rela-
tive importance and predictive capacity of the corre-
sponding variable. Although previous criteria do not 
provide a probability of having IIM, many use qualifiers 
such as possible, probable or definite IIM. By providing 
a probability, the EULAR/ACR IIM classification criteria 
permit setting the classification cut-off to specific values 
to optimise sensitivity or specificity to meet the specific 
needs of any given clinical or epidemiological setting. 
The IMCCP steering committee recommends that ‘high 
probability’ of IIM should be defined as 90% or greater.
Unlike previous myositis criteria, the EULAR/ACR IIM 
classification criteria include amyopathic DM patients as 
part of the spectrum of IIM. The patients with amyopa-
thic DM included in the study routinely received a skin 
biopsy showing interface dermatitis. Only few patients 
with IMNM were included in the study due to the fact 
that this subgroup only became better recognised once 
the study was underway.15 These patients could not be 
separated from patients with PM in the subclassification 
tree. Studies including more patients with IMNM could 
enable revising these criteria in the future to separate 
Figure 2 Classification tree for subgroups of idiopathic inflammatory myopathies (IIMs). A patient must first be classified as 
having IIM using the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification 
criteria. The patient can then be subclassified using the classification tree. The mixed (dotted outlined box) subgroup of 
patients with PM includes patients with IMNM. For IBM diagnosis, one of the following, *Finger flexor weakness and response 
to treatment: not improved or **Muscle biopsy: rimmed vacuoles, is required for diagnosis. ***Juvenile myositis other than JDM 
was developed based on expert opinion and extrapolation from adults. IMNM and hypomyopathic DM were too few to allow 
subclassification. ADM, amyopathic dermatomyositis; DM, dermatomyositis; IBM, inclusion body myositis; IMNM, immune-
mediated necrotising myopathy; JDM, juvenile dermatomyositis; PM, polymyositis.
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IMNM from the other subgroups. Although interstitial 
lung disease (ILD) is a common extramuscular manifes-
tation in adult IIM and yielded a strong association with 
having IIM in the dataset, it is not a common manifesta-
tion in juvenile IIM. Dysphagia displayed equally strong 
weight as ILD and was judged more clinically relevant to 
include in classification criteria by the myositis experts.
The EULAR/ACR IIM classification criteria offer 
advantages over previously published myositis criteria. 
First, they contain symptoms and measurements that are 
easily clinically accessible and do not require extra effort 
or costs of the clinic. The only invasive procedure in the 
new criteria involves muscle biopsies, but an alternative 
set of criteria was optimised for use when muscle biopsy 
data are unavailable. The IMCCP steering committee, 
however, recommends that muscle biopsy data be 
included when none of the skin manifestations is present. 
Similarly, especially when no muscle disease exists, it is 
recommended that a skin biopsy be performed. The new 
criteria offer flexibility that other criteria may lack. Not all 
items in the EULAR/ACR IIM classification criteria need 
to be evaluated. Clinicians may stop measuring items as 
soon as a sufficiently high or low probability is obtained. 
All the items in the EULAR/ACR IIM classification 
criteria are defined unambiguously. This is important, as 
subjective and inconsistent interpretations have marred 
accuracy and practicability of previous criteria. In addi-
tion, face and content validity was secured by ensuring 
the continued involvement of an extended panel of 
myositis experts throughout the entire process. The cases 
and comparators were random samples of the respective 
populations, and the prevalence of IIM in our data was 
61% (976 cases and 624 comparators). Therefore, the 
probability of IIM provided by the EULAR/ACR IIM clas-
sification criteria is most accurate when the IIM preva-
lence in the population of patients in which the criteria 
are applied is about 60%.
The web calculator may prove a practical aid in clas-
sifying patients in clinical and research settings alike. 
When sufficient information is entered, the subclassifi-
cation is also displayed. It is available for any electronic 
devices, such as computers and smartphones. A Microsoft 
Excel spreadsheet is also available for download.
Conclusions
The new EULAR/ACR classification criteria for IIM 
provide the probability of having IIM for any given 
patient, based on easily measurable characteristics. In 
internal-data and external-data validations, the new 
criteria demonstrated great accuracy in predicting IIM as 
well as all of the IIM subgroups and were approved by an 
international panel of myositis experts.
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